Journal
LEUKEMIA
Volume 23, Issue 2, Pages 271-278Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2008.310
Keywords
FIP1L1; PDGFRA; Eos-MPN
Categories
Funding
- Deutsche Jose Carreras Leuka r mie-Stiftung eV-DJCLS [R06/02, H03/01]
- Leukaemia Research Fund, UK
- German Bundesministerium fur Bildung und Forschung [eVF01GI9980/6]
- European Community
- AIRC
- [NCI-CA89032]
- [FIRB2006]
Ask authors/readers for more resources
The FIP1L1-PDGFRA fusion gene is a recurrent molecular abnormality in patients with eosinophilia-associated myeloproliferative neoplasms. We characterized FIP1L1-PDGFRA junction sequences from 113 patients at the mRNA (n = 113) and genomic DNA (n 85) levels. Transcript types could be assigned in 109 patients as type A (n = 50, 46%) or B (n = 47, 43%), which were created by cryptic acceptor splice sites in different introns of FIP1L1 (type A) or within PDGFRA exon 12 (type B). We also characterized a new transcript type C (n = 12, 11%) in which both genomic breakpoints fell within coding sequences creating a hybrid exon without use of a cryptic acceptor splice site. The location of genomic breakpoints within PDGFRA and the availability of AG splice sites determine the transcript type and restrict the FIP1L1 exons used for the creation of the fusion. Stretches of overlapping sequences were identified at the genomic junction site, suggesting that the FIP1L1-PDGFRA fusion is created by illegitimate non-homologous end-joining. Statistical analyses provided evidence for clustering of breakpoints within FIP1L1 that may be related to DNA-or chromatin-related structural features. The variability in the anatomy of the FIP1L1-PDGFRA fusion has important implications for strategies to detect the fusion at diagnosis or for monitoring response to treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available